# Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

> **NCT03106038** · PHASE1,PHASE2 · COMPLETED · sponsor: **Li-Cor, Inc.** · enrollment: 41 (actual)

## Conditions studied

- Intraoperative Ureter Injury

## Interventions

- **DRUG:** Nerindocianine for Injection

## Key facts

- **NCT ID:** NCT03106038
- **Lead sponsor:** Li-Cor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-26
- **Primary completion:** 2018-11-19
- **Final completion:** 2018-11-19
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03106038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03106038, "Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03106038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*